Astrazeneca (AZN) ended the recent trading session at $75.57, demonstrating a +1.79% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.49% gain on the day. On the ...

The AstraZeneca PLC ADR AZN rose 1.79% to $75.57 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

The National Institutes of Health, which falls under the jurisdiction of HHS, has terminated grants for research into vaccine hesitancy, according to the Washington Post, even though the Texas measles ...

Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

The Yorl business said it is now signing multiple new contracts with global market-leading pharmaceutical companies ...

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients.

York-based biotech firm, the Aptamer Group, has reported “revenue growth, solid cash position and strong technical progress” in its ...

The founders of Bugworks Research are attempting to bring to market a new class of antibiotics--a first in almost half a ...

Astrazeneca AB has synthesized antibody-drug conjugates comprising an antibody or antigen-binding fragment covalently linked to cytotoxic moieties through enzymatically cleavable linkers reported to ...